ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

ClinicalTrials.gov ID: NCT07076212

Public ClinicalTrials.gov record NCT07076212. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study Evaluating NALIRIFOX Versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Study identification

NCT ID
NCT07076212
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Medical University of South Carolina
Other
Enrollment
52 participants

Conditions and interventions

Interventions

  • 5-Fluorouracil Drug
  • Cisplatin Drug
  • Gemcitabine (mg/m²) Drug
  • Leucovorin Drug
  • Liposomal Irinotecan Drug
  • Nab-paclitaxel Drug
  • Oxaliplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 1, 2026
Primary completion
Apr 30, 2028
Completion
Oct 31, 2029
Last update posted
May 5, 2026

2026 – 2029

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Hollings Cancer Center at Medical University of South Carolina Charleston South Carolina 29425 Recruiting
Medical University of South Carolina Hollings Cancer Center Charleston South Carolina 29425 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07076212, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07076212 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →